Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKLB1028 versus salvage chemotherapy in relapsed or refractory FLT3-mutated acute myeloid leukemia
ChiCTR2000041448Phase 3Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ruserontinib in acute myeloid leukemia (AML) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: CR/CRh and EFS. Started Jan 2021; status: recruiting.
02
Drugs
ruserontinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2000041448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041448.